The Development of selective and potent Kv1.3 ion channel blockers for the treatment of multiple sclerosis
The Development of selective and potent Kv1.3 ion channel blockers for the treatment of multiple sclerosis
开发用于治疗多发性硬化症的选择性强效 Kv1.3 离子通道阻滞剂
批准号：
nhmrc : 406698
负责人：
Dr Andrew Harvey
金额：
$15.55万
依托单位国家：
澳大利亚
项目类别：
Early Career Fellowships
财政年份：
2006
资助国家：
澳大利亚
项目状态：
已结题
起止时间：
2006-01-01 至 2009-12-31
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Building on the well-established path of developing drugs from Nature, the amplification of some unusual qualities of a naturally-occurring substance, khellinone, could lead to new treatments for autoimmune diseases such as multiple sclerosis and diabetes. Designed variants of khellinone are known to be very effective at preventing the destructive impact of the body's own T cells on the central nervous system that occurs in autoimmune disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
新型M4受体选择性拮抗剂的研究
-
批准号：30973615
-
项目类别：面上项目
-
资助金额：32.0万元
-
批准年份：2009
-
负责人：何新华
-
依托单位：
